European marketing authorisation of hepatitis B surface antigen (Heplisav B) for immunisation against hepatitis B virus infection

Approval of this two-dose regimen, one-month regimen vaccine was based on head-to-head clinical trials which demonstrated a statistically significantly higher seroprotection rate against all subtypes of hepatitis B vs standard three dose comparators.

Source:

Biospace Inc.